摘要
背景:结直肠癌(CRC)是一种高发肿瘤,尽管治疗方法不断更新和发展,但其治疗形势仍然十分困难。 目的:为结直肠癌患者的预后、监测和生存提供一个模型。 方法:在本研究中,我们建立了一个新的 CRC 预后模型。从GEO数据库中访问四组CRC数据,然后使用limma包和RobustRankAggreg包进行差异分析(logFoldChange>1,adjust-P<0.05),用于识别重叠差异表达基因(DEGs) )。对DEGs进行单变量和多变量Cox回归分析,筛选与患者预后相关的基因,构建五基因预后预测模型(包括RPX、CXCL13、MMP10、FABP4和CLDN23)。然后,我们进一步绘制了 ROC 曲线以评估 TCGA 数据集中五基因预后特征的预测性能(1、3、5 年生存期的 AUC 值分别为 0.68、0.632、0.675)和外部独立的数据集 GSE2962(1、3、5 年生存期的 AUC 值分别为 0.689、0.702、0.631)。 结果:结果表明,该模型能够有效预测CRC患者的预后,为CRC患者的预后提供了稳健的预测模型。 结论:该模型能够有效预测CRC患者的预后,为CRC患者的预后提供了稳健的预测模型。
关键词: 预后、特征、CRC、预测性、CLDN23、FABP4、MMP10、CXCL13。
图形摘要
Current Gene Therapy
Title:A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer
Volume: 21 Issue: 4
关键词: 预后、特征、CRC、预测性、CLDN23、FABP4、MMP10、CXCL13。
摘要:
Background: Colorectal cancer (CRC) is a kind of tumor with high incidence and its treatment situation is still very difficult despite the constant renewal and development of treatment methods.
Objective: To assist the prognosis, monitoring and survival of CRC patients with a model.
Methods: In this study, we established a new prognostic model for CRC. Four groups of CRC data were accessed from the GEO database, and then differential analysis (logFoldChange>1, adjust- P<0.05) was carried out by using the limma package along with the RobustRankAggreg package used to identify the overlapping differentially expressed genes (DEGs). Univariate and multivariate Cox regression analyses were performed on the DEGs to screen the genes related to the patient’s prognosis, and a five-gene prognostic prediction model (including RPX, CXCL13, MMP10, FABP4 and CLDN23) was constructed. Then, we further plotted ROC curves to evaluate the predictive performance of the five-gene prognostic signature in the TCGA data sets (the AUC values of 1, 3, 5-year survival were 0.68, 0.632, 0.675, respectively) and an external independent data set GSE2962 (the AUC values of 1, 3, 5-year survival were 0.689, 0.702, 0.631, respectively).
Results: The results showed that the model could effectively predict the prognosis of CRC patients, which provides a robust predictive model for the prognosis of CRC patients.
Conclusion: The model could effectively predict the prognosis of CRC patients, which provides a robust predictive model for the prognosis of CRC patients.
Export Options
About this article
Cite this article as:
A Five-gene Signature for Predicting the Prognosis of Colorectal Cancer, Current Gene Therapy 2021; 21 (4) . https://dx.doi.org/10.2174/1566523220666201012151803
DOI https://dx.doi.org/10.2174/1566523220666201012151803 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alternative Splicing and Tumor Progression
Current Genomics Safety and Complications Reporting Update on the Re-Implantation of Culture-Expanded Mesenchymal Stem Cells Using Autologous Platelet Lysate Technique
Current Stem Cell Research & Therapy Adrenomedullin: A Tumor Progression Factor via Angiogenic Control
Current Cancer Drug Targets Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Deubiquitinating Enzymes as Therapeutic Targets in Cancer
Current Pharmaceutical Design PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Himalayan Plants as a Source of Anti-Cancer Agents: A Review
The Natural Products Journal Molecular Imaging in Optical Coherence Tomography
Current Molecular Imaging (Discontinued) Defining Pharmacokinetics for Individual Patient Dosimetry in Routine Radiopeptide and Radioimmunotherapy of Cancer: Australian Experience
Current Pharmaceutical Design New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Exploring Patterns of Epigenetic Information with Data Mining Techniques
Current Pharmaceutical Design Enzymes Oxidizing the Azo Dye 1-Phenylazo-2-Naphthol (Sudan I) and their Contribution to its Genotoxicity and Carcinogenicity
Current Drug Metabolism Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Nanotechnology and Brain Tumors Drug Delivery
Recent Patents on Nanomedicine Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design Isothiocyanates as Cancer Chemopreventive Agents: Their Biological Activities and Metabolism in Rodents and Humans
Current Drug Metabolism Role of α6β4 Integrin in Cell Motility, Invasion and Metastasis of Mammary Tumors
Current Protein & Peptide Science